DAB2 and breast carcinoma: According to previous literatures [24], promoter hypermethylation of DAB2 associated with the loss expression of DAB2 in many types of human cancers, such as nasopharyngeal carcinoma [25], breast cancer [26], and esophageal squamous cell carcinomas [27].